Lilly Doubles Down on Nimbus in $1.3B Oral Obesity Pact
Nimbus Therapeutics has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to
Read moreNimbus Therapeutics has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to
Read moreParkinson’s disease (PD) is a progressive neurodegenerative condition impacting millions globally. While a blend of genetic, environmental, and ageing factors
Read moreThe cutting-edge AcuiSee device for visual acuity testing of laboratory animals stands out as a breakthrough in the realm of
Read moreSanofi has announced it has agreed to acquire Dynavax Technologies Corporation, a publicly traded vaccines company, in a move that
Read moreStriatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read moreBoosting RPE Metabolic Support Offers a Promising Gene-Independent Strategy for RP Treatment A Striatech .pdf Case Study Retinitis Pigmentosa (RP)
Read moreA recent study from Constance Cepko’s group at Harvard Medical School offers an encouraging advance toward therapeutic strategies for Retinitis
Read moreAntiinfectives Intelligence (Aii) offers state-of-the-art Time-Kill Assay services to evaluate the dynamic killing effects of antimicrobial agents. This advanced method
Read moreAerska, a newly formed biotechnology company focused on transforming the treatment of neurological diseases, has officially launched with $21 million
Read moreA recent study by Janos Groh and colleagues in Mikael Simons’ group at the Institute of Neuronal Cell Biology, Technical
Read more